63results about How to "Improve mitochondrial function" patented technology

A skin care composition is useful for augmenting cellular metabolism in skin cells and thereby enhancing the regulation of intracellular signaling. The composition comprises a primer for skin cell mitochondrial function, such as a Krebs cycle intermediate, a precursor of a Krebs cycle intermediate, salts or esters thereof, or combinations thereof. The composition may also include antioxidants for free radical regulation and a pharmaceutically acceptable topical vehicle, such as an emollient base for skin health. A method for stimulating the mitochondrial activity of skin cells comprises administering to the skin of a person in need thereof a composition as described herein.

Compositions and methods comprising bioenergetic agents for restoring the quality of aged oocytes, enhancing oogonial stem cells or improving derivatives thereof (e.g., cytoplasm or isolated mitochondria) for use in fertility-enhancing procedures, are described.

The present invention is directed to the use of (a composition comprising) hydroxytyrosol as anti-aging agent. The composition, to which the present invention is also directed, does essentially not comprise resveratrol and is administered orally to animals. The present invention is further directed to anti-aging methods. “Anti-aging” meaning in the context of the present invention: retarding the aging processes in said animals, improving age-related physiological deficits in said animals and / or promoting a healthy aging in said animals.

The present invention relates to compositions and methods for prophylactic and / or therapeutic treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more compounds selected from the group consisting of epicatechin, an epicatechin derivative, catechin, a catechin derivative, nicorandil, and a nicorandil derivative in an amount effective to stimulate mitochondrial function in cells. The methods and compositions described herein provide for reducing infarct size in the heart following permanent ischemia or ischemia / reperfusion (IR) event or method for delaying, attenuating or preventing adverse cardiac remodeling, and can assist in prevention of impaired mitochondria biogenesis and thus prevention of the consequences of impaired mitochondrial biogenesis in various diseases and conditions, as well as provide for the active therapy of mitochondrial depletion that may have already occurred.

The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1):wherein:R1 represents hydrogen or the like;R2 represents hydrogen or the like;R3 represents substituted or unsubstituted phenyl or the like;R4 represents halogen or the like;R5 represents hydrogen or the like;R6 represents hydrogen or the like; andR7 represents hydrogen or the like.

The invention relates to a caviar composition capable of fighting against senium and belongs to the technical field of cosmetics. The caviar composition comprises the ingredients in parts by weight: 5-15 parts of caviar extract, 2-5 parts of herba artemisiae apiaceae extract, 0.05-1 part of acetyl hexapeptide-8, 0.5-2 parts of arginine / lysine polypeptide, 0.8-2.0 parts of carnosine and 0.5-1.2 parts of tripeptide-1 copper. The composition comprises different effective ingredients and a reasonable ratio, and all active ingredients are in mutual synergism and can infiltrate into a deep layer ofskin; and the aging of skin cells is decelerated by means of moisturizing, activating, repairing, protecting and the like, so that the composition has the actions of improving skin elasticity, reducing skin roughness and thinning wrinkles. In addition, the composition also has an obvious effect in the aspects of eliminating free radicals, resisting skin inflammation and protecting and repairing cells.

The invention discloses a preparation method of leukocyte extract. Neonate cord blood is used directly as a raw material subjected to human lymphocyte separation density-gradient centrifugation to obtain PBMCs (peripheral blood mononuclear cells); amplification culture is performed via cord serum separated from the cord blood; centrifugal separating is performed to obtain supernate; leukocyte extract is acquired by ultra-filtration. The preparation method has no need for bovine serum, no heterogeneous animal proteins or stimulating factors are involved, and safety of application in human bodies is good. The leukocyte extract prepared via the method has rich natural human cellular factors, wherein bFGF (basic fibroblast growth factor) reaches 60 pg / ml and above, the yield is high, and the production cost is low. The invention also provides application of the leukocyte extract in the activation and restoration of cells. The leukocyte extract may be added to cosmetics to provide synergy with other components in cosmetic formulations; the leukocyte extract can cooperate to improve cell mitochondrial functionality, complete nutrients for cell metabolism are provided, and the cell activating function of the leukocyte extract is significantly improved.

Compositions and methods comprising bioenergetic agents for restoring the quality of aged oocytes, enhancing oogonial stem cells or improving derivatives thereof (e.g., cytoplasm or isolated mitochondria) for use in fertility-enhancing procedures, are described.

Alzheimer's disease is treated using THC (alone, or in combination with melatonin) administered in an ultra-low dose amount sufficient to (i) reduce Aß expression; (ii) reduce Aß aggregation: (iii) maintain APP expression; (iv) enhance mitochondrial functioning; (v) decrease phosphorylation of GSK3ß protein; (vi) decrease the expression of GSK3ß protein; (vii) decrease phosphorylation of Tau protein; and / or (viii) maintain Tau protein expression, in said patient without severe psychological impairments and side effects associated with higher doses of THC.

Methods for modifying neuronal functional activity and / or treating a neurological disorder by using agents that raise neuronal intracellular concentration of magnesium are disclosed. Also provided herein are methods of determining the amenability of an individual to treatment for a neurological disorder, by measuring changes in intracellular magnesium concentration.

The invention discloses a composition. The composition contains a silybum marianum extract and fructose 1, 6 diphosphate or a derivative thereof, or a salt thereof. The silybum marianum extract is ina silybum marianum extract microcapsule form and / or a silybum marianum extract liposome form and / or a silybum marianum extract self-microemulsifying form, and the composition of the silybum marianum extract and FDP has the effects of reducing liver injury, preventing hangover and resisting fatigue, and particularly can quickly take effect to reduce liver injury and quickly sober up.

The invention discloses creatine derivatives that are represented by Formula (I), Formula (II), and Formula (III); wherein Z is a functional group; Y is a mitochondrial targeting agent, a cationic ammonium group, or a polypeptide containing at least one positively charged amino acid residue; each R1 is independently hydrogen, alkyl, or a phosphate group; R2 a linker; R3 is a spacer group; R4 is hydrogen, alkyl, aryl, or heterocyclic; or R4 and R1, or R4 and R3, together with the nitrogen atoms to which they are attached form a heterocyclic ring, and W is hydrogen or alkyl.

The present invention relates to the use of melatonin for the preparation of a pharmaceutical composition suitable for intratumoral administration for the treatment of tumors. This composition comprises high concentrations of melatonin, melatonin derivatives or metabolites, such that melatonin exerts an oxidizing effect, increasing the production of free radicals and activating cell death.

The invention belongs to the technical field of biological medicine, and relates to a method for improving in-vitro and in-vivo maturation quality of oocytes and application of the method. Melatonin is directly added into an in-vitro maturation culture solution of the oocytes, female animals take in the melatonin, and the melatonin is proved to be capable of relieving quality reduction of the oocytes induced by oxybenzophenone. The application has the advantages that the in-vitro and in-vivo maturation rate of oocytes and the development rate of early embryos are increased, the spindle body morphology and the mitochondrial function are improved, the ROS level in the oocytes is reduced, the GSH level is increased, and the early apoptosis level is inhibited. The invention provides a method for improving the influence of oxybenzophenone on the quality of female animal oocytes, and the method has important significance for diagnosis and treatment of patients with abnormal maturation of oocytes caused by environmental factors clinically and in-vitro production of animal embryos.

The present invention provides modified metformin compounds, particularly mito-metformin compounds, and pharmaceutical compositions thereof. Methods of using the compounds to provide neuroprotection and in the treatment and / or prevention of neurodegenerative diseases are also described.

Methods and compositions relating to isolated mitochondria are disclosed. For example, cells, tissues, or organs can be treated with isolated mitochondria, such as porcine mitochondria, to improve mitochondrial function in the cell, tissue, or organ. The improvements to mitochondrial function include increased oxygen consumption and increased ATP synthesis. Such methods and compositions are useful for cell therapy; organ and tissue transplantation; organ and tissue engineering; and cold storage or shipment of harvested organs, tissues, and cells.

The present invention relates to a composition for preventing or treating mitochondrial diseases caused by immunosuppressants, and immune diseases, containing metformin and, more specifically, to a composition for treating mitochondrial diseases caused by immunosuppressants, containing metformin; a pharmaceutical composition for preventing or treating immune diseases, containing, as active ingredients, metformin and an immunosuppressant, which is a target of rapamycin inhibitor (mTOR inhibitor); and a pharmaceutical composite formulation for preventing or treating immune diseases, containing, as ingredients, metformin and a mammalian target of rapamycin inhibitor, wherein the metformin and mammalian target of rapamycin inhibitor are administered simultaneously or separately, or administered in a predetermined sequence. The composition effectively alleviates mitochondrial dysfunction, occurring as a side effect of conventional immunosuppressants, while having a more improved immunosuppressive therapeutic effect, thereby being usable in prevention and treatment of transplant rejection, autoimmune diseases, inflammatory diseases, and the like, all of which require immunosuppression.

The invention relates to a lamp for preventing eyestrain and belongs to the field of eye protection lamp development. The lamp with light which is soft and close to natural light is developed by an inventor by improving spectra of a light source in the prior art in order to reduce fatigues of human eyes caused by light-emitting diodes (LEDs) and risks color weakness. The lamp for preventing eyestrain comprises a lamp holder which is composed of a group of luminous sources, and each luminous source comprises an LED lamp, a far-infrared lamp and a fluorescent lamp (or a filament lamp). The light sent out by the lamp has the advantages of having a full-spectral characteristic similar to the natural light, being high in soft performance and good in color rendition, and being capable of improving blood flow volume of vessels on eyes, reducing intraocular pressure and relieving the eyestrain.

The present invention is directed to a functional chewing gum comprising a gum base and active ingredients boosting in mental clarity and concentration, wherein said active ingredients are selected among Shilajit, Ashwagandha, coenzyme Q10, L-Tirosine, Rhodiola, Bacopa monnieri, L-Alpha glycerylphosphorylcholine (alpha-GPC), Guayusa, Phosphatidylserine (preferably GMO free), and piperine (i.e. blackpepper extract). The present invention is also directed to a functional chewing gum comprising a gum base and active ingredients providing alleviation of fatigue and enhancement of energy, wherein said active ingredients are selected among Shilajit, coenzyme Q10, citrulline malate, Siberian Ginseng, L-Tyrosine, Ganoderma lucidum (Reishi), Hericium erinaceus (Lion's mane), Coconut Oil powder, Shilajit, Guayusa, Resveratrol and piperine (blackpepper extract).

Disclosed in certain embodiments is a pharmaceutical composition comprising a sugar; a Krebs cycle intermediate, precursor of a Krebs cycle intermediate, salt thereof, or combination thereof; and a component selected from the group consisting of an unsaturated lipid, phenylethylamine, a soluble calcium compound, or a combination thereof.

The invention relates to the field of medicines, and particularly relates to an application of notoginsenoside R1. Experiments prove that NTR1 can be used for improving the cognition, learning and memory capabilities of an APP / PS1 transgenic AD mouse, restoring the intracerebral ChAT level of the mouse, reducing the intracerebral malondialdehyde level, and improving the mitochondrial function of the AD mouse by improving the CcO activity. In addition, the NTR1 also can be used for increasing the IDE level so as to promote degradation of A beta and inhibit the accumulation of the A beta. Therefore, the invention further provides the application of the notoginsenoside R1 to preparation of a medicament for treating an alzheimer disease. Moreover, experiments prove that the notoginsenoside R1 causes no influences to cell viability within a concentration range of 0-500 micromoles, so the notoginsenoside R1 is proved to be safe in medication.

The invention discloses an intestinal mitochondrial functional protector for alleviating heat stress in broiler chickens, wherein the intestinal mitochondrial functional protector consists of 5-10 parts by weight of a ginkgo leaf extract, 6-10 parts by weight of chlorogenic acid, 5-10 parts by weight of betaine and 10-25 parts by weight of palygorskite. Compared with addition of the ginkgo leaf extract, chlorogenic acid, betaine and palygorskite separately in a feed, the protector can significantly alleviates heat stress in the broiler chickens, significantly increases the intestinal mitochondrial autophagy level under heat stress in the broiler chickens and improves intestinal mitochondrial functions of heat stress in the broiler chickens. The four components have significant interactionin increasing mitochondrial function of the broiler chickens and mitochondrial autophagy level, and have positive synergistic combined effect. The palygorskite has controlled-release effect on the ginkgo leaf extract, chlorogenic acid and betaine, the ginkgo leaf extract, chlorogenic acid and betaine are allowed to be easily mixed with a feed, a uniform dispersion system is formed and use is convenient. Through the synergistic effect of all the components, the level of mitochondrial autophagy under heat stress in the broiler chickens is significantly improved, and the intestinal mitochondrialfunction injury caused by heat stress is significantly alleviated.

Compositions and methods comprising bioenergetic agents for restoring the quality of aged oocytes, enhancing oogonial stem cells or improving derivatives thereof (e.g., cytoplasm or isolated mitochondria) for use in fertility-enhancing procedures, are described.

A skin care composition is useful for augmenting cellular metabolism in skin cells and thereby enhancing the regulation of intracellular signaling. The composition comprises a primer for skin cell mitochondrial function, such as a Krebs cycle intermediate, a precursor of a Krebs cycle intermediate, salts or esters thereof, or combinations thereof. The composition may also include antioxidants for free radical regulation and a pharmaceutically acceptable topical vehicle, such as an emollient base for skin health. A method for stimulating the mitochondrial activity of skin cells comprises administering to the skin of a person in need thereof a composition as described herein.

The invention discloses application of a mitochondrial function intervention material in preparation of health care products or drugs for improving mitochondrial function and a screening method thereof. The method includes: constructing a mitochondrial damage model by palmitic acid; determining acyl carnitine by LC-MS / MS method; detecting respiratory function by a Seahorse extracellular flux analyzer; conducting quantitative PCR detection on mitochondrial DNA content; conducting real-time quantitative PCR detection on mRNA level expression of genes mainly related to mitochondria; detecting mitochondrial related genes and oxidized phosphorylated complex protein in skeletal muscle by Western blot method; detecting MDA content and NAD+ / NADH content by a kit; and observing the ultrastructure of cell mitochondria by a transmission electron microscope and conducting morphological analysis. Compared with the existing evaluation screening system, the evaluation screening system provided by theinvention is more scientific, accurate and efficient.

The disclosure relates to mitochondrial myocyte enhancer factor 2 (MEF2), Parkinson's disease, and other related diseases. In certain embodiments, the disclosure relates to analyzing the levels of mitochondrial MEF2 isoforms and / or its mitochondrial target gene ND6 in peripheral blood cells such as white blood cells as an indicator for neuronal mitochondrial MEF2 or ND6 and correlated the level to disease diagnosis, treatment, and prognosis.

The present invention relates to pharmaceutical compositions active in preventing, stabilizing and treating Alzheimer's disease and cognitive dysfunctions related thereto.